News

Phase 1b trial launched of inhaled nintedanib for pulmonary fibrosis

Avalyn Pharma has initiated a Phase 1b clinical trial to test AP02, a therapeutic candidate for pulmonary fibrosis (PF), in adult healthy volunteers. The placebo-controlled trial of inhaled nintedanib will assess its safety, tolerability, and pharmacological profile when given at single or multiple ascending doses. Its main goal…

US patent covers brilaroxazine in treating IPF, like diseases

Reviva Pharmaceuticals has been awarded a U.S. patent covering the use of its experimental therapy brilaroxazine in treating people with pulmonary fibrosis. The patent, No. 12053477, granted by the U.S. Patent and Trademark Office specifically covers the use of brilaroxazine in idiopathic pulmonary fibrosis (IPF), as well…

Partnership will bring Brainomix AI-powered tool to US centers

Brainomix, a U.K.-based software company, has joined forces with Boehringer Ingelheim, a German pharmaceutical company, to accelerate the diagnosis of pulmonary fibrosis (PF) in the U.S. and improve treatment access for people with scarring of the lungs. As part of the collaboration, Brainomix’s artificial intelligence (AI)-powered tool, called Brainomix 360…

Enrollment complete for Phase 2a trial of IPF treatment BBT-877

Enrollment has been completed for a Phase 2a study that’s testing idiopathic pulmonary fibrosis (IPF) treatment BBT-877, an investigational therapy from Bridge Biotherapeutics. The Phase 2a trial (NCT05483907) is evaluating the safety, tolerability, and efficacy of BBT-877 in 120 adults with IPF, ages 40 and older, with or…

Enrollment complete for Phase 3 trial testing Tyvaso in IPF patients

Enrollment is complete for a Phase 3 clinical trial testing Tyvaso (treprostinil) inhalation solution for idiopathic pulmonary fibrosis (IPF), United Therapeutics, the therapy’s developer, said. The TETON 2 study (NCT05255991) will evaluate the treatment’s safety and efficacy in 597 adults with IPF, 40 years and older,…

UW-Madison researchers get nearly $11M to study what drives IPF

An interdisciplinary group of researchers at the University of Wisconsin (UW)-Madison have received nearly $11 million to study the biological processes that promote lung scarring in idiopathic pulmonary fibrosis (IPF). Funding comes from a four-year grant (HT94252410543) provided by the U.S. Department of Defense. The research will be…

IPF treatment AGMB-447 granted FDA orphan drug status

AGMB-447, an inhaled treatment for idiopathic pulmonary fibrosis (IPF) now being tested in a Phase 1 clinical trial, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to therapies that may improve care for people with rare diseases,…

Lixudebart for IPF receives orphan drug status from FDA

The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan drug designation is given to support the accelerated development of investigational treatments for rare diseases, defined as those affecting fewer than 200,000…